


Cite this: *RSC Adv.*, 2021, 11, 21857

Compartmentalized cross-linked enzyme nano aggregates (*c*-CLEnAs) toward pharmaceutical transformations†

M. Teresa de Martino,^{‡a} Fabio Tonin,^{‡b} Victor R. L. J. Bloemendal,^{‡ac} Ulf Hanefeld,^{id* b} Floris P. J. T. Rutjes^{id* c} and Jan C. M. van Hest^{id* a}

A new immobilization strategy using compartmentalized nanoreactors is herein reported for two biocatalytic processes: (1) *N*-acetylneuraminate lyase (NAL) is internalized in NAL-*c*-CLEnAs and used in a continuous flow aldol condensation of *N*-acetyl-D-mannosamine with sodium pyruvate to *N*-acetylneuraminic acid; (2) two hydroxysteroid dehydrogenases (HSDH) 7 α - and 7 β -HSDH are incorporated in *c*-CLEnAs and used in a two-step cascade batch synthesis of ursodeoxycholic acid (UDCA). The versatile use of *c*-CLEnA demonstrates that this immobilization methodology is a valuable addition to the toolbox of synthetic chemists.

Received 4th June 2021
Accepted 14th June 2021

DOI: 10.1039/d1ra04332c

rsc.li/rsc-advances

In the recent decade, there has been an ongoing search for effective implementation of enzymes in flow catalysis and multistep synthesis.^{1–6} The use of enzymes in flow can be highly beneficial as it allows combination of the stereo and substrate selectivity of the biocatalysts with excellent control in mass and heat transfer of the flow process.^{7,8} In addition, flow applications with enzymes allow for improved kinetic control, as reactions can be steered away from equilibrium to obtain higher conversions, which is difficult to achieve in batch reactions. All this makes flow catalysis a green and environmentally benign approach for pharmaceutically relevant transformations.^{8–12} However, to make these biocatalytic processes economically feasible, enzyme recycling is often required, which necessitates enzymes to be immobilized and retained in the flow reactor. Although many immobilization strategies have been developed, they are often hampered by a loss of activity as a result of the conjugation or adsorption method employed and/or of the reduced accessibility of the catalytic sites.¹

To address this issue, recently, nanoreactors have been developed which can accommodate different catalytic species, allow effective substrate access and simplify workup operations.^{13–16} In our previous work, we created nanoreactors based

on bowl-shaped poly(ethylene-glycol)-*b*-polystyrene (Fig. S1†) polymer vesicles, named stomatocytes, which could be loaded with enzymes in their nanocavity. Upon treatment with a crosslinking agent we obtained compartmentalized cross-linked enzyme *nano* aggregates (*c*-CLEnA) (Fig. S2†) which were shown to be beneficial for preserving the native enzymatic activity. In the case of combined-cross-linking of two enzymatic species, they resulted in enhanced activity.^{17–19} Additionally, *c*-CLEnAs proved to be stably loaded with enzymes with minimal leaching during flow operations.¹⁷ Until now, the concept of *c*-CLEnAs was demonstrated with robust model enzymes. In order to indicate the added value for the fine chemical and pharmaceutical industry, in this work we have investigated two applications for *c*-CLEnAs as efficient biocatalytic nanoreactors for a continuous flow aldol condensation and a one-pot biocatalytic two-step reaction (Fig. 1) toward useful pharmaceutical intermediates.

For the first example, we focused on *N*-acetylneuraminate lyase (NAL, EC 4.1.1.3) which is a well-studied enzyme for the preparation of neuraminic acid derivatives (Neu5Ac).^{20,21} Moreover, NAL demonstrates high substrate variability and enzymatic stability (Fig. 1I). Neu5Ac and its derivatives have a high relevance from a pharmacological point of view since they are involved in a range of physiological processes.²⁰ Derivatives of Neu5Ac have for example been used to inhibit the neuraminidases of influenza viruses A and B in a clinical setting and they are known to prevent avian influenza.^{22,23} NAL has already been encapsulated in cross-linked enzyme aggregates (CLEA)²⁴ and cross-linked inclusion bodies (CLIB)^{25,26} which were both effective in retaining enzymatic activity but were challenging to prepare. In other studies, NAL has been immobilized on immobeads, but this process required considerable quantities

^aDepartment of Chemical Engineering & Chemistry, Institute for Complex Molecular Systems, Eindhoven University of Technology, PO Box 513, 5600 MB Eindhoven, The Netherlands. E-mail: J.C.M.v.Hest@tue.nl

^bDepartment of Biotechnology, Delft University of Technology, Van der Maasweg 9, 2629 HZ Delft, The Netherlands. E-mail: u.hanefeld@tudelft.nl

^cInstitute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands. E-mail: floris.rutjes@ru.nl

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1ra04332c

‡ Equal contribution.






Fig. 1 Compartmentalized-cross-linked enzyme nano-aggregates *c*-CLEnAs for the execution of enzymatic transformations with pharmaceutical relevance (I) NAL-*c*-CLEnAs for a continuous flow synthesis of Neu5Ac; (II) Combined 7 α /7 β -HSDH *c*-CLEnAs for a one-pot cascade reaction to UDCA.

of enzymes to produce reasonable amounts of Neu5Ac.²⁰ We hypothesized that using *c*-CLEnAs as a novel immobilization strategy for NAL would allow the effective implementation of this nanoreactor in a flow process with more economical use of the enzyme.

Secondly, the two enzymes 7 α - and 7 β -hydroxysteroid dehydrogenase (7 α -HSDH and 7 β -HSDH) were encapsulated in stomatocyte nanoreactors to enable the cascade reaction for the synthesis of ursodeoxycholic acid (UDCA) (Fig. 1II).²⁷ The chemical transformation to UDCA, starting from chenodeoxycholic acid (CDCA), can be performed by 7 α -HSDH and 7 β -HSDH that are respectively NAD⁺ and NADH dependent.²⁷ UDCA is an important secondary bile acid that is used as a pharmaceutical product in the clinic to improve liver function and solubilize cholesterol gallstones.^{28,29} Traditionally, the non-enzymatic route for UDCA production involves many reaction steps, including the use of hazardous and toxic solvents and the final product is only recovered in a low yield (~30%).³⁰ To make the synthesis more effective an enzymatic route has been developed, starting from cholic acid (CA), the cheapest bile acid available. The route entails C12 dehydroxylation, followed by 7-OH epimerization. For the latter process 7 α -HSDH and 7 β -HSDH work in a cascade fashion. The 7 α -OH group of CDCA is oxidized by 7 α -HSDH, with the concomitant reduction of NAD⁺ to NADH. The obtained compound (7-oxo-lithocholic acid, 7-oxo-LCA) is subsequently reduced to the final product (UDCA) by 7 β -HSDH that utilizes the NADH produced in the first reaction. Notably, this epimerization reaction is carried out in a redox-neutral manner, where the equilibrium between CDCA and UDCA is solely thermodynamically determined. Optimization of this enzymatic route can be achieved by an effective immobilization of these two complementary enzymes, allowing for an easy separation from the final product, without hampering their activity and without creating diffusional barriers for the substrates and cofactors. With this in mind, we

developed the co-immobilization of 7 α -HSDH and 7 β -HSDH in the same *c*-CLEnA nanoreactors, hypothesizing that the close proximity of the two species in the nanosized cavity of the stomatocytes would bring additional stability and high reactivity to this cascade.

In previous reports it was described that NAL is a selective but rather slow converting enzyme. As a result, to make continuous flow production of Neu5Ac feasible, the loading of NAL was an important design aspect to take into consideration.²⁰ Therefore, the preparation of NAL-*c*-CLEnAs required optimization from the previously described procedure.¹⁷ In the first instance it was attempted to create stomatocyte samples with a loading efficiency of ~30% (loading efficiency calculated by Bradford assay, corresponding to 3 mg mL⁻¹ of enzyme encapsulated starting from 10 mg mL⁻¹ NAL solution). The enzyme was subsequently cross-linked with either genipin (1 wt%) or glutaraldehyde (100–300 mM).³¹ However, these formulations showed severe problems. The formation of aggregates at the bottom of the solution was observed in the case of glutaraldehyde cross-linking, which was accompanied by a complete deactivation of the enzyme. As observed before, the fast reaction with glutaraldehyde resulted in denaturation of the enzymes. Furthermore, the high enzyme loading led to cross-linking between particles, causing precipitation. When a solution (1 wt%) of the milder cross-linking agent genipin was used for the NAL-*c*-CLEnA preparation this latter problem was resolved. However, also in this case enzyme activity was negligible. This was not observed when using *ca.* 14% loaded samples (1.4 mg NAL loaded in 500 μ L of 10 mg mL⁻¹ stomatocytes). Enzyme activity was preserved and no aggregation was observed. This NAL-*c*-CLEnA was subsequently used for the flow experiments (Table S1[†]).

Several solutions of 14% loaded NAL-*c*-CLEnAs were tested in the continuous flow aldol reaction of a stock solution of *N*-acetyl-D-mannosamine (1) and sodium pyruvate (2) using a membrane reactor (Table S1[†]). For ensuring a NAL loading of at least 20 mg in the membrane reactor, 10 mL samples (10 mg mL⁻¹) were concentrated to 3 mL and the final solution was loaded in the membrane. The catalytic activity was investigated by varying flow rates, temperature, and also the type of membrane (Table S1[†]). When 500 mM of (1) and 100 mM of (2) were fed at 35 $^{\circ}$ C over a modified poly(ether sulfone) (mPES) membrane (10 kDa) at 20 μ L min⁻¹ 69% yield of Neu5Ac was observed. At higher temperatures (50 $^{\circ}$ C), the activity was decreased to 50%. Increasing the flow rate resulted in a lower conversion, as expected. However, for the highest flow rate tested (100 μ L min⁻¹) the conversion was still 35%.

The obtained conversions were comparable to previous results reported.²⁴ Still, the use of NAL-*c*-CLEnA effectively decreased enzyme loading by a factor of ~3, thus increasing the turnover number of NAL. Furthermore, the stability of NAL-*c*-CLEnAs in flow was also object of our investigation (Fig. 2).

For the stability experiments, the flow setup was based on a hollow fiber reactor with a membrane of mixed cellulose ether (ME) with 0.1 μ m pore size. This membrane was chosen as it would allow for the retention of the polymeric nanovesicles in the tubular reactor but not of the enzymes in case of leaching.






Fig. 2 Stability test of NAL-*c*-CLEnA in a continuous flow setup. Conditions: ManNAc (2, 500 mM), sodium pyruvate (3, 100 mM), H₂O, NAL-*c*-CLEnA (3 mL of 0.34 g mL⁻¹, containing 18 mg of NAL). 25 μL min⁻¹, 35 °C. Conversions determined by ¹H NMR analysis of the crude reaction mixture (Fig. S3†).

Based on earlier results with *c*-CLEnAs leaching could be ruled out and with this experiment we could therefore specifically focus on enzyme deactivation.¹⁷

The conditions were set to ensure a conversion below 50%, in order to have a more accurate insight in the change of conversion over time as a function of deactivation. Gratifyingly, when NAL-*c*-CLEnAs were continuously tested in the flow reactor for a week, Neu5Ac formation was still observed. The use of NAL immobilized-beads resulted in ~33% loss in activity in a previous report;²⁰ we proved that our NAL-*c*-CLEnAs demonstrated similar stability (~31% loss after the same period).

The *c*-CLEnA system cannot only be useful for application in flow systems, but the nano-assembly method also allows to bring enzymes together that operate in a cascade fashion. This was demonstrated with the enzymatic redox-neutral epimerization of CDCA. Recently, this reaction has been carried out by employing two enzymes (7α-HSDH and 7β-HSDH).²⁷ Here a batch reaction is highly favoured over the flow approach. In flow the cofactor would be flushed away and the reaction could then not be performed in a redox neutral manner anymore.

The enzymes were produced and purified according to literature.²⁷ To probe for proximity effects, different nano-reactors were prepared by encapsulating the two enzymatic species either separately or together. Firstly, the two enzymes were encapsulated separately, leading to the construction of 7α-HSDH-*c*-CLEnAs and 7β-HSDH-*c*-CLEnAs, both with a loading efficiency of 25% (2 mg of enzyme loaded in 500 μL of 10 mg mL⁻¹ sample). The optimal amount of genipin needed for the cross-linking of the enzymes was established by analysing the residual specific activity of the enzymes after encapsulation and cross-linking. Similarly to the NAL-*c*-CLEnAs, using glutaraldehyde as cross-linker deactivated both enzymes significantly suggesting that using a faster bifunctional cross-linker might not be suitable for these particular enzymes. In contrast to the previous example with NAL none of the *c*-CLEnAs showed the formation of clustering or sedimentation. When a genipin solution at 1 %wt was used to cross-link the samples the activity of both enzymes was conserved. Notably, batch-to-batch

variations were observed using different amounts of genipin (Table S2†). Next, the co-encapsulation of the two enzymes in a single nanoreactor was investigated. Ideally, co-encapsulation is advantageous since it reduces the diffusion limitations of the reagents and cofactors (CDCA/7-oxo-LCA and NAD⁺/NADH). The encapsulation and cross-linking processes were carried out using the same procedure as for the single enzyme encapsulation; therefore, to 25% loaded 7α/7β-HSDH stomatocyte samples (2 mg of total enzyme mixture loaded in the sample), 1 wt% genipin was added to afford 7α/7β-HSDH *c*-CLEnAs. A sample of co-encapsulated enzymes without cross-linking (7α/7β-HSDH stomatocytes, 25% loading efficiency) was used as control to evaluate the effect of the cross-linking step on the enzymatic activities. Notably, stomatocytes with non-crosslinked enzymes and *c*-CLEnA showed similar activities. This indicates that, the enzymes conserved their activity when a milder cross-linker as genipin is used. To establish the applicability of the newly obtained nanoreactors for the epimerization of CDCA into UDCA, a series of bioconversions was performed (Fig. 3).

When the cascade reaction was performed using the co-encapsulated enzymes 7α and 7β-HSDH in stomatocytes or in *c*-CLEnAs (Fig. 3A and B) no significant differences between the two nanoreactors were observed. Using a catalyst loading of 200–300 μg (equivalent to 1.5 U and 0.9 U of 7α- and 7β-HSDH activity, respectively) and 1 mM of NAD⁺, 8.6 mM (conversion 86%) and 8.7 mM (conversion 87%) of UDCA were obtained after 200 min using 7α/7β-HSDH stomatocytes and 7α/7β-HSDH *c*-CLEnA, respectively. In comparison to literature in which the free enzymes were used, the reaction with *c*-CLEnA showed




Fig. 3 Bioconversion of 10 mM CDCA into UDCA with 1 mM of NAD⁺ by using (A) co-encapsulated 7α/7β-HSDH *c*-CLEnA (B) co-encapsulated 7α/7β-HSDH stomatocytes (C) 7α + 7β-HSDH in separate *c*-CLEnAs. (D) Bar plot reporting the amount of UDCA (mM) formed after 24 h reaction with 0.5 mM and 1 mM of NAD⁺. 7-Oxo-LCA is the intermediate product 7-oxo-lithocholic acid.



comparable rates and conversion values.³⁰ In addition, when a catalyst loading of 20–30 μg (equivalent to 0.15 U and 0.09 U of 7 α - and 7 β -HSDH activity, respectively) was used, 9.0 mM of UDCA was obtained, (90% conversion) after 24 h using both kinds of preparations. Similar conversions were obtained when 0.5 mM NAD^+ was used (Fig. 3D). On the other hand, when bioconversions were performed at similar conditions using separately encapsulated 7 α + 7 β -HSDH *c*-CLENAs (1 U_{TOT} of 7 α HSDH *c*-CLENAs (2.6 μg) and 0.8 U_{TOT} of 7 β -HSDH *c*-CLENAs (133 μg)) lower activities were observed (Fig. 3C). When 1 mM of NAD^+ was used, 6.2 mM (62% conversion) and 6.7 mM (67% conversion) of UDCA were obtained after 200 min and 24 h, respectively. Additionally, when 0.5 mM of NAD^+ was used with separately encapsulated 7 α + 7 β -HSDH *c*-CLENAs, only 2.2 mM of UDCA (22% conversion) was obtained after 24 h (Fig. 3D).

Our experiments suggest that having the enzymes encapsulated in two different compartments poses an additional barrier to the substrate/co-factor diffusion to activate the second step of the cascade, impacting the final conversion which is considerably lower compared to the free enzyme cascade.

This is especially visible when the co-factor concentration is lowered, and the final conversion is 22%. However, this is not observed with the 7 α /7 β -HSDH *c*-CLENAs and stomatocytes in which the bioconversions show good agreement with the cascade reaction performed with the 7 α and 7 β -HSDH as free enzymes. In these systems there is no diffusional constraint for the second enzymatic conversion. This demonstrates that the co-encapsulation in stomatocytes allows the cascade reaction to be performed without negative effects on conversion, but with the potential benefit of easy catalyst recovery.

In summary, *c*-CLENAs were implemented for the *N*-acetylneuraminic acid lyase mediated production of Neu5Ac in flow, and for the bioconversion of CDCA to UDCA via 7 α -HSDH and 7 β -HSDH. Both nanoreactor systems showed to be inactive when cross-linked using glutaraldehyde but gratifyingly retained enzymatic activity upon controlled crosslinking with genipin. For the *N*-acetylneuraminic acid lyase synthesis, the NAL-*c*-CLENAs were loaded in a hollow fiber membrane flow reactor. After optimizing the reaction conditions by using a modified polyethersulfone reactor and low flow rates a conversion of 69% to Neu5Ac was achieved. Although this yield did not outrank previous results with the immobead-NAL, it effectively decreased enzyme loading by a factor of three, thus increasing the turnover number of the neuraminic acid lyase. The stability of the NAL-*c*-CLENAs was further demonstrated in a continuous experiment for 168 hours with a moderate loss in their activity. Regarding the cascade to UDCA, the activity of the two enzymes was preserved after cross-linking the two enzymes in the same stomatocytes with genipin, and no significant difference was observed between the not crosslinked enzyme-loaded stomatocytes and the *c*-CLENAs. However, the combined *c*-CLENAs proved to be more active than when the two enzymes were compartmentalized in separated *c*-CLENAs, especially at lower concentrations of the cofactor NADH. This demonstrates that two pharmaceutically relevant transformations can be effectively performed with the outlined systems, indicating that

this technology can be broadly applied in biocatalysis for drug synthesis.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We kindly acknowledge the funding by the H2020-FETOPEN-2016-2017 programme of the European Commission (Grant agreement number: 737266-ONE FLOW).

References

- 1 M. P. Thompson, I. Peñafiel, S. C. Cosgrove and N. J. Turner, *Org. Process Res. Dev.*, 2019, **23**, 9–18.
- 2 M. Guidi, P. H. Seeberger and K. Gilmore, *Chem. Soc. Rev.*, 2020, **49**, 8910–8932.
- 3 R. M. Lindeque and J. M. Woodley, *Catalysts*, 2019, **9**, 262.
- 4 W. Ahle and O. Misset, *Biotechnology*, 2008, **5**, 189–216.
- 5 R. A. Sheldon and S. van Pelt, *Chem. Soc. Rev.*, 2013, **42**, 6223–6235.
- 6 U. Hanefeld, *Chem. Soc. Rev.*, 2013, **42**, 6308.
- 7 J. Britton, S. Majumdar and G. A. Weiss, *Chem. Soc. Rev.*, 2018, **47**, 5891–5918.
- 8 P. De Santis, L. Meyer and S. Kara, *React. Chem. Eng.*, 2020, **5**, 2155–2184.
- 9 M. Santi, L. Sancineto, V. Nascimento, J. Braun Azeredo, E. V. Orozco, L. H. Andrade, H. Gröger and C. Santi, *Int. J. Mol. Sci.*, 2021, **22**, 990.
- 10 C. J. Hartley, C. C. Williams, J. A. Scoble, Q. I. Churches, A. North, N. G. French, T. Nebl, G. Coia, A. C. Warden, G. Simpson, A. R. Frazer, C. Nixon Jensen, N. J. Turner and C. Scott, *Nat. Cat.*, 2019, **2**, 1006–1015.
- 11 M. P. van der Helm, P. Bracco, H. Busch, K. Szymańska, A. B. Jarzębski and U. Hanefeld, *Catal. Sci. Technol.*, 2019, **9**, 1189.
- 12 B. Bouchaut, L. Asveld, U. Hanefeld and A. Vlierboom, *Int. J. Environ. Res. Public Health*, 2021, **18**, 1963.
- 13 D. M. Vriezema, P. M. L. Garcia, N. Sancho Oltra, N. S. Hatzakis, S. M. Kuiper, R. J. M. Nolte, A. E. Rowan and J. C. M. Van Hest, *Angew. Chem., Int. Ed.*, 2007, **46**, 7378–7382.
- 14 M. C. M. van Oers, F. P. J. T. Rutjes and J. C. M. van Hest, *Curr. Opin. Biotechnol.*, 2014, **28**, 10–16.
- 15 A. Küchler, M. Yoshimoto, S. Luginbühl, F. Mavelli and P. Walde, *Nat. Nanotechnol.*, 2016, **11**, 409–420.
- 16 M. T. De Martino, L. K. E. A. Abdelmohsen, F. P. J. T. Rutjes and J. C. M. van Hest, *Beilstein J. Org. Chem.*, 2018, **14**, 716–733.
- 17 M. T. De Martino, F. Tonin, N. A. Yewdall, M. Abdelghani, D. S. Williams, U. Hanefeld, F. P. J. T. Rutjes, L. K. E. A. Abdelmohsen and J. C. M. Van Hest, *Chem. Sci.*, 2020, **11**, 2765–2769.
- 18 C. Cui, H. Chen, B. Chen and T. Tan, *Appl. Biochem. Biotechnol.*, 2017, **181**, 526–535.



- 19 Q. Ji, B. Wang, J. Tan, L. Zhu and L. Li, *Process Biochem.*, 2016, **51**, 1193–1203.
- 20 V. R. L. J. Bloemendal, S. J. Moons, J. J. A. Heming, M. Chayoua, O. Niesink, J. C. M. van Hest, T. J. Boltje and F. P. J. T. Rutjes, *Adv. Synth. Catal.*, 2019, **361**, 2443–2447.
- 21 X. Zhou, G. Yang and F. Guan, *Cells*, 2020, **9**, 273.
- 22 A. Bianco, M. Brufani, R. Ciabatti, C. Melchioni and V. Pasquali, *Mol. Online*, 1998, **2**, 129–136.
- 23 F. Tao, Y. Zhang, C. Ma and P. Xu, *Sci. Rep.*, 2011, **1**, 142.
- 24 M. I. García-García, A. Sola-Carvajal, G. Sánchez-Carrón, F. García-Carmona and Á. Sánchez-Ferrer, *Bioresour. Technol.*, 2011, **102**, 6186–6191.
- 25 J. Nahálka, A. Vikartovská and E. Hrabárová, *J. Biotechnol.*, 2008, **134**, 146–153.
- 26 M. I. García García, A. Sola Carvajal, F. García Carmona and Á. Sánchez Ferrer, *Process Biochem.*, 2014, **49**, 90–94.
- 27 F. Tonin, L. G. Otten and I. W. C. E. Arends, *ChemSusChem*, 2019, **12**, 3192–3203.
- 28 J. L. Thistle, *Semin. Liver Dis.*, 1983, **3**, 146–156.
- 29 T. Ikegami and Y. Matsuzaki, *Hepatol. Res.*, 2008, **38**, 123–131.
- 30 F. Tonin and I. W. C. E. Arends, *Beilstein J. Org. Chem.*, 2018, **14**, 470–483.
- 31 O. Barbosa, C. Ortiz, Á. Berenguer-Murcia, R. Torres, R. C. Rodrigues and R. Fernandez-Lafuente, *RSC Adv.*, 2014, **4**, 1583–1600.

